Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DiaNe consultation and support program · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| with DiaNe program | ACTIVE_COMPARATOR | study subjects which participated in the DiaNe consultation and support program |
| without DiaNe program | NO_INTERVENTION | study subjects which received standard care by diabetologist and/or nephrologist |
| Name | Type | Description |
|---|---|---|
| DiaNe consultation and support program | BEHAVIORAL | the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks |
Inclusion Criteria: * diabetes mellitus * proven diabetic nephropathy by histological/lab findings and/or discretion of nephrologist * ability to understand the German language Exclusion Criteria: * end stage renal disease and/or dialysis * unable or unwilling to follow the protocol * pregnant wo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| DexCom, Inc. | DXCM | 1 | PHASE3 | Sotagliflozin |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | ALN-ANG3, Evinacumab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| ProKidney Corp. Class A | PROK | 2 | - | Renal Autologous Cell Therapy |
DiaNe is a consultation and support program for people with diabetic nephropathy, a kidney condition caused by diabetes. It is designed to provide guidance and assistance to patients managing this condition. The program is currently in Phase 3 clinical development and is being studied in Germany.
DiaNe is developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY. The company is conducting clinical research on the DiaNe program for diabetic nephropathy.
DiaNe is in Phase 3 clinical development. It is an investigational program, meaning it is still being studied and has not yet been approved for general use. The Phase 3 trial for DiaNe has been completed.
DiaNe has one completed Phase 3 clinical trial with the identifier NCT00782847. The trial, titled 'Evaluation Study for the Programme DiaNe for People With Diabetic Nephropathy,' enrolled 125 participants in Germany. The study was active-controlled and included a biomarker-selected patient population.
No alternative names for DiaNe have been reported. It is referred to solely as DiaNe in clinical trial records. The program is distinct in its focus as a consultation and support program rather than a traditional pharmaceutical drug.